BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

Core Insights - BioCardia, Inc. has reported promising late-breaking echocardiography results from its Phase III clinical trial for ischemic heart failure with reduced ejection fraction (HFrEF), indicating a potential reduction in negative remodeling of heart volumes in treated patients [1][3]. Clinical Results - The clinical results were presented by Dr. Amish Raval at the Technology and Heart Failure Therapeutics (THT) conference, highlighting the effectiveness of autologous CardiAMP cell therapy in reducing pathological left ventricular remodeling over time compared to control patients [2][3]. - Treated patients showed a statistically significant reduction in left ventricular end diastolic volume (p = 0.06) and left ventricular end systolic volume (p = 0.09), with clinically meaningful differences in a subgroup with elevated biomarkers of heart stress [3][4]. Treatment Implications - CardiAMP treatment is associated with less adverse cardiac remodeling in patients with elevated NTproBNP levels, a biomarker of myocardial stress, suggesting its potential benefits in targeted patient subgroups [4][5]. - The results from the CardiAMP-HF trial indicate a promising avenue for addressing the growing burden of heart failure, particularly as current pharmaceutical options have limited impact [5]. Company Overview - BioCardia is a leader in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with its CardiAMP autologous cell therapy receiving FDA Breakthrough designation [6][7]. - The company is developing three cardiac clinical stage product candidates and utilizes advanced biotherapeutic delivery platforms [7].